Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma.
OBJECTIVE
To determine the efficiency of topical cyclosporine-A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC).


METHODS
Interventional case reports.


METHODS
Two patients who had positive margins following surgical excision of CCSC were treated by topical CSA (0.05%) four times a day for 12 weeks, and topical MMC (0.01%) four times a day was combined with CSA at the second, fourth, and sixth weeks of the treatment. We controlled the tumor recurrence, vision, and ocular surface healing during the follow-up.


RESULTS
There was no tumor recurrence during the follow up of 18 months. Limbal vascularization regressed considerably and the vision improved without any ocular surface problems in both patients.


CONCLUSIONS
As an adjunctive treatment, topical CSA (0.05%) combined with MMC (0.01%), may prevent tumor recurrence and provide excellent ocular surface healing in diffuse CCSC.
Tunc
Murat
M
Department of Ophthalmology, Abant Izzet Baysal University Düzce Medical School, Düzce, Turkey. mtunc@isbank.net.tr
Erbilen
Esin
E
D000287:Administration, Topical; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D016685:Mitomycin; D016572:Cyclosporine